Corbus stockholders approve 2024 Equity Compensation Plan reserving 2M shares

Corbus Pharmaceuticals Holdings, Inc.

Stockholders approved 2024 Equity Compensation Plan, reserving 2,000,000 shares of common stock for issuance under options, SARs, restricted stock, RSUs, and performance awards.
All eight director nominees (Yuval Cohen, Alan Holmer, Avery Catlin, Rachelle Jacques, John Jenkins, Peter Salzmann, Anne Altmeyer, Yong Ben) were elected with at least 6.19M votes for each.
Ratification of EisnerAmper LLP as independent auditor for fiscal 2024 approved with 8,388,012 votes for.
Advisory vote on executive compensation passed with 6,593,949 votes for, 44,363 against, and 1,962,726 broker non-votes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.